Solventum Corporation (SOLV) Stock
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Solventum Corporation is led by CEO Bryan C. Hanson, employs 20,000 people, headquartered in Maplewood, US, publicly traded since 2024.
Solventum Corporation (SOLV) stock trades at $86.17 with a market capitalization of $14.92B. The stock is valued at a price-to-earnings (P/E) ratio of 8.57, price-to-book of 2.61, price-to-sales of 1.57. Over the past 52 weeks the stock has ranged between $62.38 and $88.20, and currently trades 2.3% below its 52-week high.
On profitability, Solventum Corporation generates a return on equity (ROE) of 30.82% — well above the market average, a sign of a high-quality business, return on capital employed of 43.20%, an operating margin of 26.20%, a net profit margin of 17.33%.
Official website: www.solventum.com